Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06972472 · ClinicalTrials.gov registry record · Phase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

A Phase 3 study of Obesity and Type 2 Diabetes, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 3
Development phase
600
Enrollment target
20
Study locations

NCT06972472 is a Phase 3 study of Obesity and Type 2 Diabetes that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 600 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06972472, a Phase 3 study of Obesity and Type 2 Diabetes, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 3
Development phase
600 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.

Conditions Studied

Obesity Type 2 Diabetes Overweight

Interventions

  • DRUG Placebo
  • DRUG Orforglipron

Study Locations (20)

Florida

  • Accel Research Sites - DeLand Clinical Research Unit - DeLand
  • Innovation Medical Research Center - Fort Lauderdale - Fort Lauderdale
  • Indago Research & Health Center, Inc - Hialeah
  • Encore Medical Research - Hollywood
  • West Orange Endocrinology P.A. - Ocoee
  • Care Access - Tampa - Tampa

Georgia

  • Accel Research Sites - NeuroStudies Clinical Research Unit - Decatur
  • Care Access - Decatur - Decatur
  • Javara - Privia Medical Group Georgia - Savannah - Savannah
  • North Georgia Clinical Research - Woodstock

California

  • Norcal Endocrinology & Internal Medicine - San Ramon
  • Southern California Clinical Research - Santa Ana
  • Care Access - Thousand Oaks - Thousand Oaks

Arizona

  • Clinical Research Institute of Arizona (CRI) - Sun City West - Sun City West
  • Novak Clinical Research - Tucson - North La Cholla Boulevard - Tucson

Maryland

  • Endocrine and Metabolic Consultants - Rockville
  • Javara - Privia Medical Group - Silver Spring - Silver Spring

Idaho

  • Solaris Clinical Research - Meridian

Louisiana

  • Care Access - New Iberia - New Iberia

Montana

  • Boeson Research MSO - Missoula

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2025-05-19
Est. Completion 2027-08
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06972472

The ClinicalTrials.gov registry entry for NCT06972472 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (27% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06972472 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Georgia, California.

Frequently Asked Questions

What is clinical trial NCT06972472 about?

NCT06972472 is a clinical study titled "A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes". The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.

What is the current status of trial NCT06972472?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-05-19. Estimated completion is 2027-08.

What conditions does trial NCT06972472 study?

This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, Overweight.

What interventions are being tested in trial NCT06972472?

The interventions under investigation include: Placebo (DRUG), Orforglipron (DRUG).

Who is sponsoring clinical trial NCT06972472?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06972472 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Type 2 Diabetes

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.